The Thunderbolt device from California-based Penumbra uses modulated aspiration to detect and remove blood clots. Back in January, Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion.
Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific.
The exam should be performed on patients with greater than 10 years of life expectancy and between the ages of 50 and 70, with earlier imaging recommended for black men.
Lawmakers have opted against authorizing funding for the Wasteful and Inappropriate Service Reduction Model, citing concerns it will overburden patients and providers.
The collaboration between the chipmaker and Abridge, a developer of generative AI for healthcare, will involve data-sharing to improve Nvidia’s general-purpose models, which in turn will be used to make Abridge’s clinical offerings more efficient.
Anthony Weinert, DPM, said the reputational harm he suffered as a result of the 2019 healthcare fraud charges has left him unable to find work, despite the case being voluntarily withdrawn by authorities.
The Kentucky-based insurance giant had owned a 40% stake in the hospice company, stemming from its 2021 acquisition of Kindred Healthcare. Humana said a “consortium of investors" is making the buy, but few details were revealed.
New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary.
Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.
Recor Medical's Paradise Ultrasound Renal Denervation System is the first medical device approved for the treatment of hypertension in Japan. It first gained FDA approval back in 2023.
The Thunderbolt device from California-based Penumbra uses modulated aspiration to detect and remove blood clots. Back in January, Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion.
Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific.
